<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05793229</url>
  </required_header>
  <id_info>
    <org_study_id>Nanjing Medical University</org_study_id>
    <nct_id>NCT05793229</nct_id>
  </id_info>
  <brief_title>Frailty Trajectories and Their Association With Health Outcomes</brief_title>
  <official_title>Exploration of Frailty Trajectories and Their Association With Health Outcomes in Elderly Gastric Cancer Survivors Undergoing Radical Gastrectomy: a Prospective Longitudinal Observation Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanjing Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Frailty is common in gastric cancer survivors and seriously affects their prognosis. Multiple&#xD;
      longitudinal follow-up assessment of frailty could provide a better understanding of the&#xD;
      frailty change of individuals. Our aims were to identify the longitudinal trajectories of&#xD;
      frailty and estimate their association with health outcomes in elderly gastric cancer&#xD;
      survivors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Our study suggested the significant heterogeneity in frailty trajectories among elderly&#xD;
      gastric cancer survivors, and that different trajectories had different effects on health&#xD;
      outcomes. Our results infer the necessity for prevention strategies in elderly gastric cancer&#xD;
      survivors to manage heterogeneous frailty trajectories.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2021</start_date>
  <completion_date type="Actual">February 1, 2023</completion_date>
  <primary_completion_date type="Actual">October 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>quality of life (QOL)</measure>
    <time_frame>at 1-year after surgery</time_frame>
    <description>used EORTC QLQ-STO22 to assess.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>disability</measure>
    <time_frame>at 1-year after surgery</time_frame>
    <description>used Elderly Disability Assessment Scale to assess.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>1-year hospital readmissions</measure>
    <time_frame>at 1-year after surgery</time_frame>
    <description>captured from medical records.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>total costs</measure>
    <time_frame>at 1-year after surgery</time_frame>
    <description>captured from medical records.</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">381</enrollment>
  <condition>Frailty Syndrome</condition>
  <arm_group>
    <arm_group_label>improving frailty</arm_group_label>
    <description>Class 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>maintaining frailty</arm_group_label>
    <description>Class 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>deteriorating frailty</arm_group_label>
    <description>Class 3</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>observation</intervention_name>
    <description>observation</description>
    <arm_group_label>deteriorating frailty</arm_group_label>
    <arm_group_label>improving frailty</arm_group_label>
    <arm_group_label>maintaining frailty</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Elderly patients with gastric cancer who attended a tertiary care hospital in China from&#xD;
        March 2021 to October 2021 were selected for the study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  diagnosed with gastric cancer by endoscopy or pathology;&#xD;
&#xD;
          -  received radical gastrectomy the first time;&#xD;
&#xD;
          -  aged â‰¥60 years;&#xD;
&#xD;
          -  been able to communicate simply in writing and verbal;&#xD;
&#xD;
          -  completed the data collection of all follow-up points.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  received radiotherapy or chemotherapy before surgery;&#xD;
&#xD;
          -  had other sites of malignant tumors;&#xD;
&#xD;
          -  complicated with severe heart, liver, lung and renal insufficiency;&#xD;
&#xD;
          -  had physical disability.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Xueyi Miao</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>211166</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>March 19, 2023</study_first_submitted>
  <study_first_submitted_qc>March 19, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">March 31, 2023</study_first_posted>
  <last_update_submitted>March 19, 2023</last_update_submitted>
  <last_update_submitted_qc>March 19, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nanjing Medical University</investigator_affiliation>
    <investigator_full_name>Xueyi Miao</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Frailty</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

